Follow
Fredrik Piehl
Fredrik Piehl
Professor of neurology, Karolinska Institutet
Verified email at ki.se
Title
Cited by
Cited by
Year
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Nature 476 (7359), 214-219, 2011
30982011
Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ...
Nature Reviews Neurology 14 (10), 577-589, 2018
17622018
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ...
Nature genetics 45 (11), 1353-1360, 2013
13862013
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium*†, ANZgene, ...
Science 365 (6460), eaav7188, 2019
10772019
Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium
TGM Van Erp, E Walton, DP Hibar, L Schmaal, W Jiang, DC Glahn, ...
Biological psychiatry 84 (9), 644-654, 2018
8132018
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind …
JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ...
The Lancet Neurology 16 (12), 976-986, 2017
6842017
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ...
JAMA neurology 76 (9), 1035-1048, 2019
6702019
Risk factors for amyotrophic lateral sclerosis
C Ingre, PM Roos, F Piehl, F Kamel, F Fang
Clinical epidemiology, 181-193, 2015
5882015
Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis
I Jelcic, F Al Nimer, J Wang, V Lentsch, R Planas, I Jelcic, A Madjovski, ...
Cell 175 (1), 85-100. e23, 2018
4902018
Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies
G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ...
JAMA neurology 77 (2), 184-191, 2020
4812020
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
L Novakova, H Zetterberg, P Sundström, M Axelsson, M Khademi, ...
Neurology 89 (22), 2230-2237, 2017
4432017
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
M Gunnarsson, C Malmeström, M Axelsson, P Sundström, C Dahle, ...
Annals of neurology 69 (1), 83-89, 2011
4172011
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
M Swanberg, O Lidman, L Padyukov, P Eriksson, E Åkesson, M Jagodic, ...
Nature genetics 37 (5), 486-494, 2005
4152005
Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy
J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ...
Neurology 87 (20), 2074-2081, 2016
4092016
Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ...
Multiple Sclerosis Journal 21 (8), 1013-1024, 2015
3992015
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ...
The Lancet Neurology 21 (3), 246-257, 2022
3892022
Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells
H Hammarberg, O Lidman, C Lundberg, SY Eltayeb, AW Gielen, ...
Journal of Neuroscience 20 (14), 5283-5291, 2000
3762000
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ...
The Lancet Neurology 19 (4), 307-316, 2020
3722020
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open …
R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ...
The Lancet Neurology 17 (5), 405-415, 2018
3672018
T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived …
M Khademi, Z Illés, AW Gielen, M Marta, N Takazawa, C Baecher-Allan, ...
The Journal of Immunology 172 (11), 7169-7176, 2004
3242004
The system can't perform the operation now. Try again later.
Articles 1–20